Current Headlines

  1. Ventus Therapeutics Enters Into A Collaboration And License Agreement With Genentech To Discover And Develop Small-Molecule Medicines Using Ventus' ReSOLVE Platform 10/21/2025

    Ventus Therapeutics, a clinical-stage biopharmaceutical company advancing two Phase 2 small-molecule programs for immunological, inflammatory, and neurological disorders, today announced a multi-year collaboration with Genentech, a member of the Roche Group, to discover and optimize novel small-molecule candidates for challenging targets in major disease areas using Ventus’ proprietary drug discovery platform, ReSOLVE.

  2. Samsung Bioepis And Phrontline Announce A Global Strategic Partnership To Advance Best-In-Class Antibody-Drug Conjugate Therapeutics For Solid Tumors 10/20/2025

    Samsung Bioepis Co., Ltd. and Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the companies have entered into a global collaboration agreement to develop, manufacture and commercialize two ADC assets: TJ108, bispecific and dual-payload ADC, and another asset to be named.

  3. Charles River And X-Chem Announce Strategic Collaboration To Enhance Hit Identification Capabilities 10/20/2025

    Charles River Laboratories International, Inc. today announced a strategic collaboration with X-Chem, Inc., the pioneer in DNA-encoded library (DEL) technology and a data-driven drug discovery company, to enhance its hit identification (Hit ID) capabilities and accelerate the discovery of novel therapeutics.

  4. Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation For KPL-387 For The Treatment Of Pericarditis 10/17/2025

    Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to KPL-387 for the treatment of pericarditis, which includes recurrent pericarditis.

  5. New Drug Shows Dramatic Effect In Shrinking Lung Cancer Tumours 10/17/2025

    A new drug is having a dramatic effect on shrinking lung cancer tumours, according to new research.

  6. New Discovery: Antipsychotic Drugs Could Inhibit Fungal Resistance Mechanisms 10/16/2025

    Invasive fungal infections have become a growing global health threat, claiming more than 6.5 million lives annually.

  7. Indivi And Clouds Of Care Partner To Advance Deep Phenotyping In Early Alzheimer's And Parkinson's Drug Development 10/15/2025

    Indivi and Clouds of Care, two independent TechBio companies, today announced a strategic partnership to advance the use of precision medicine tools in early-phase neuroscience drug development, targeting Alzheimer’s and Parkinson’s disease.

  8. Syngene International Invests In Dedicated Peptide Laboratory And Advanced Automation 10/15/2025

    Syngene International, a global contract research, development, and manufacturing organization (CRDMO), announced site upgrades to accelerate drug discovery and development, helping clients bring novel therapies to market faster.

  9. Chiesi Announces FDA Acceptance Of New Drug Application For Its Triple Combination Inhaler For The Maintenance Treatment Of Asthma 10/15/2025

    Chiesi USA, Inc. (key-A-zee), a biopharmaceutical company that supports patients in living their best possible lives through life-changing or lifesaving innovations, today announced that the U.S. Food and Drug Administration has accepted the company’s New Drug Application (NDA) for its investigational maintenance treatment of asthma in adults.

  10. Leiden Researchers Pioneer 'Green' Framework For Sustainable Drug Development 10/14/2025

    Medical drugs are expensive to make and can have an adverse effect on the environment.